Sartorius (SRT) CMD 2026 summary

Strategic direction and innovation

• Focus on accelerating drug development, process intensification, and advanced therapies, leveraging AI, automation, and advanced cell models to address industry needs for speed, efficiency, and cost-effectiveness.

• Commitment to remain a pure-play biopharma partner with an end-to-end portfolio, emphasizing innovation leadership through targeted M&A, partnerships, and internal R&D.

• Expansion into high-growth areas such as single-use technologies, advanced therapy solutions, and bioanalytics, with a strong push for digitalization and data-driven insights.

• Customer experience and operational excellence are prioritized, aiming for reliable supply, simplified processes, and best-in-class support.

• Heavy investment in AI, automation, and digital platforms to drive productivity, cost efficiency, and lean operations, showcased in the Factory of the Future initiative.

Financial guidance and market outlook

• Midterm organic revenue growth targeted at 8%-11% for the group, with bioprocessing at 9%-12% and lab products/services at 5%-7%.

• EBITDA margin expansion of 50-75 basis points per year expected, driven by operational leverage, cost discipline, and digitalization.

• CapEx normalization anticipated post-2027, returning to historical levels (~9% of turnover), following major investments in global capacity.

• Free cash flow generation expected to strengthen, with disciplined capital allocation, focus on organic deleveraging, and maintaining investment grade rating.

• Market growth assumptions: bioprocess solutions market growing 8%-10%, lab products/services at 4%-6%, with above-market growth driven by innovation and portfolio expansion.

Regional and business segment dynamics

• U.S. expected to remain the fastest-growing market, followed by Asia (notably Korea and India), with Europe and China showing potential depending on local innovation and policy.

• Single-use technology penetration in commercial manufacturing is a key growth lever, with ambitions to reach mid-teens growth rates in select product areas.

• Advanced cell models and AI-powered analytics are seen as double-digit growth opportunities, with investments in platforms and acquisitions like MatTek.

• Margin targets for lab products/services are set lower than bioprocessing due to market growth rates, peer benchmarks, and deliberate investments in future technologies.

• Inventory normalization and operational improvements are expected to support margin recovery to pre-pandemic levels over time.